Taiho Oncology Appoints Peter Melnyk as President & Chief Executive Officer
Taiho Oncology, Inc., a company developing and commercializing novel treatments for hematologic malignancies and solid tumors, announced today Peter Melnyk has been appointed to President & Chief Executive Officer, effective immediately. Mr. Melnyk succeeds Tim Whitten, who has retired after 13 years of service.
Peter Melnyk Joins Taiho Oncology as President & Chief Operating Officer
Taiho Oncology, Inc., a company developing and commercializing novel treatments for hematologic malignancies and solid tumors, announced today Peter Melnyk has joined the company as President & Chief Operating Officer.
